Table 4.

Recently discontinued trials in Alport syndrome

Anti-miR-21	The HERA Phase 2 trial tested inhibitors of micro-RNA-21 which have been shown to drive kidney fibrosis. Unfortunately, the trial was prematurely terminated due to no evidence of improvement in the rate of kidney function decline [50]. (Clinical Trial Number NCT02855268)
Bardoxolone methyl	The CARDINAL trial in 2017 involved 157 Alport syndrome people living with Alport syndrome. Initially promising, but a high number of serious adverse events, treatment discontinuation, and non-significant results in post-trial analysis [51]. (Clinical Trial Number NCT03019185)